Ara
Toplam kayıt 8, listelenen: 1-8
Meme kanserli hastalarda kemoterapi sonrası bilişsel fonksiyonların aktivite performansı ve aktivite katılım üzerine olan etkisi
(AVES, 2021)
Amaç: Bilişsel fonksiyon problemleri kemoterapinin en yaygın yan etkileri arasında yer almaktadır. Bireyler tedavi bittikten sonra da bilişsel fonksiyon bozuklukları yaşamaya devam etmektedir. Meme kanseri atlatan bireyler ...
Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey
(Zerbinis Publications, 2021)
Purpose: The purpose of this study was to investigate the prognostic value,and the effect of primary tumor location on targeted therapy selection in patients with metastatic colorectal cancer (mCRC). Methods: A total of ...
Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102
(Zerbinis Publications, 2019)
Purpose: To assess whether regorafenib and TAS-102 treatments are associated with a change in Skeletal Muscle Area (SMA) as well as to compare Skeletal Muscle Mass (SMM) loss levels between regorafenib and TAS-102 treatments ...
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study
(Imprimatur Publications, 2020)
Purpose: The purpose of this study was to determine whether primary tumor localization may be a risk factor for relapse and survival in seminomatous germ cell tumors (GCT) patients.Methods: In our study, 612 seminomatous ...
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
(Imprimatur Publication, 2020)
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of ...
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
(NLM (Medline), 2023)
Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy ...
The prognostic utility of the metastatic lymph node ratio and the number of regional lymph nodes removed from patients with small bowel adenocarcinomas
(MDPI, 2023)
Background and Objectives: Small bowel adenocarcinomas (SBAs) are rare tumors of the gastrointestinal system. Lymph node metastasis in patients with curatively resected SBAs is associated with poor prognosis. In this study, ...
Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: A multicenter analysis
(Turkiye Klinikleri, 2023)
Background/aim: Oligometastatic disease for nonsmall cell lung cancer (NSCLC) patients is generally thought to represent a better prognosis with a quieter biology, limited number of disease sites and long-term disease ...